Giacomini Mita
Centre for Health Economics and Policy Analysis, Department of Clinical Epidemiology and Biostatistics, McMaster University, 1200 Main Street West, HSC-3H1C, Hamilton, Ontario L8N 3Z5, Canada.
Milbank Q. 2005;83(2):193-223. doi: 10.1111/j.1468-0009.2005.00344.x.
Health plans often deliberate covering technologies with challenging purposes, effects, or costs. They must integrate quantitative evidence (e.g., how well a technology works) with qualitative, normative assessments (e.g., whether it works well enough for a worthwhile purpose). Arguments from analogy and precedent help integrate these criteria and establish standards for their policy application. Examples of arguments are described for three technologies (ICSI, genetic tests, and Viagra). Drawing lessons from law, ethics, philosophy, and the social sciences, a framework is developed for case-based evaluation of new technologies. The decision-making cycle includes (1) taking stock of past decisions and formulating precedents, (2) deciding new cases, and (3) assimilating decisions into the case history and evaluation framework. Each stage requires distinctive decision maker roles, information, and methods.
医疗保健计划常常会慎重考虑是否涵盖那些目标、效果或成本具有挑战性的技术。它们必须将定量证据(例如,一项技术的效果如何)与定性的、规范性评估(例如,它是否足以实现有价值的目标)相结合。类比论证和先例论证有助于整合这些标准,并为其政策应用确立标准。文中描述了针对三种技术(胞浆内单精子注射、基因检测和伟哥)的论证示例。借鉴法律、伦理、哲学和社会科学的经验,开发了一个基于案例的新技术评估框架。决策周期包括:(1)总结过去的决策并制定先例;(2)裁决新的案例;(3)将决策纳入案例历史和评估框架。每个阶段都需要不同的决策者角色、信息和方法。